Non-randomized, open label phase II trial evaluating the safety and efficacy of taxotere (T) followed by myocet (M) + cyclophosphamide (C) as first-line treatment for HER2-negative breast cancer (BC)

Autor:	Calvo Martínez, Lourdes, García Mata, Jesús, López López, Rafael, Castellanos Diez, Javier
Rok vydání:	2011
Zdroj:	RUNA. Repositorio da Consellería de Sanidade e Sergas Servizo Galego de Saúde (SERGAS)
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c858d0697e1752569da3208f049f4bb7 http://hdl.handle.net/20.500.11940/2883 Zobrazit plný text záznamu